Enfusion (NYSE:ENFN) Trading Down 6.2%

Shares of Enfusion, Inc. (NYSE:ENFNGet Rating) traded down 6.2% during mid-day trading on Monday . The company traded as low as $7.85 and last traded at $7.88. 5,323 shares were traded during mid-day trading, a decline of 98% from the average session volume of 276,447 shares. The stock had previously closed at $8.40.

A number of equities analysts have issued reports on the stock. The Goldman Sachs Group decreased their price objective on shares of Enfusion from $24.00 to $15.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 16th. Morgan Stanley reduced their price target on shares of Enfusion from $22.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Friday, March 25th. Stifel Nicolaus reduced their price target on shares of Enfusion from $27.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday, March 21st. Zacks Investment Research downgraded shares of Enfusion from a “hold” rating to a “sell” rating in a research note on Monday, May 9th. Finally, Credit Suisse Group dropped their target price on shares of Enfusion from $25.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, March 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $18.67.

The stock’s 50-day moving average is $12.53 and its two-hundred day moving average is $16.00.

Enfusion (NYSE:ENFNGet Rating) last issued its quarterly earnings data on Thursday, March 24th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.51. The company had revenue of $31.85 million for the quarter, compared to the consensus estimate of $30.52 million. On average, equities analysts forecast that Enfusion, Inc. will post 0.13 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the stock. Dragoneer Investment Group LLC raised its position in Enfusion by 1.1% in the first quarter. Dragoneer Investment Group LLC now owns 6,490,000 shares of the company’s stock worth $82,553,000 after acquiring an additional 67,779 shares during the period. Hhlr Advisors LTD. bought a new position in Enfusion in the fourth quarter worth approximately $104,180,000. Alliancebernstein L.P. bought a new position in Enfusion in the fourth quarter worth approximately $48,717,000. TimesSquare Capital Management LLC raised its position in Enfusion by 8.8% in the first quarter. TimesSquare Capital Management LLC now owns 1,631,305 shares of the company’s stock worth $20,750,000 after acquiring an additional 131,280 shares during the period. Finally, BlackRock Inc. raised its position in Enfusion by 3.9% in the first quarter. BlackRock Inc. now owns 1,342,703 shares of the company’s stock worth $17,079,000 after acquiring an additional 49,953 shares during the period. Institutional investors own 61.18% of the company’s stock.

About Enfusion (NYSE:ENFN)

Enfusion Inc offers software-as-a-service for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It provides portfolio management system, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and order and execution management system that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.

Featured Articles

Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.